Physician profile
Hector J Cases
NPI 1265491781
$11,545.83
in general payments reported to CMS, 2019-2025
50 companies · $1,880 in 2025
The $1,880 reported for 2025 was more than what 77% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,914 · 2020: $1,283 · 2021: $1,907 · 2022: $928 · 2023: $1,041 · 2024: $1,594 · 2025: $1,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,145 · Travel and Lodging: $302 · Education: $66.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,145.39 |
| Travel and Lodging | $302.30 |
| Education | $66.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,930.99 | 2019-2025 | Relistor |
| Medtronic USA, INC. | $1,281.29 | 2019-2020 | |
| Nalu Medical, INC. | $1,062.38 | 2021-2025 | Nalu Neurostimulation System |
| Curonix LLC | $1,003.28 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $810.25 | 2019-2025 | Proclaim |
| Nevro Corp. | $796.53 | 2019-2024 | Senza |
| Abbvie INC. | $655.70 | 2021-2025 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $415.28 | 2019-2021 | |
| Amgen INC. | $404.91 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $357.66 | 2019-2024 | Belbuca, Xtampza |
| Boston Scientific Corporation | $323.55 | 2019-2025 | General - Pain Management, Intracept, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $199.23 | 2021-2025 | Inceptiv, Intellis Adaptivestim |
| Axonics, INC. | $197.01 | 2020 | |
| Biodelivery Sciences International, INC. | $193.31 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $148.74 | 2021 |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Cases listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.